Skip to content
Review

Abstract 15794: Prevalence and Clinical Relevance of Antiphospholipid Antibodies in Venous Thromboembolism: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: While antiphospholipid antibodies (aPL) are mechanistically linked to venous thromboembolism (VTE), the prevalence of aPL among patients with VTE remains incompletely characterized and estimates of their association with first and recurrent VTE vary across individual studies. Methods: We systematically searched PubMed and Embase examining the prevalence of aPL positivity- defined as positivity for anticardiolipin antibodies (aCL), anti-β2 glycoprotein I antibodies (aβ2GPI), and/or lupus anticoagulant functional tests as reported by each individual study- in patients with VTE to estimate pooled prevalence estimates. We separately explored the association between aPL positivity and a first or recurrent VTE using random-effects models to report odds ratios (ORs) with 95% confidence intervals (CIs). Prespecified subgroup analyses assessed consistency of findings across study designs (case-control vs cohort) and VTE risk contexts (unselected populations, unprovoked VTE, transient provoking factors, and cancer-associated VTE). Results: Any aPL positivity (48 studies, 10,256 patients with VTE) had a pooled prevalence of 14% (95% CI, 12%-17%) in patients with VTE. aPL positivity was associated with significantly higher odds of first VTE compared with no positivity (pooled OR 2.23; 95% CI, 1.60-3.12). Lupus anticoagulant demonstrated the strongest association (OR 4.20; 95% CI, 2.26-7.81), followed by aβ2GPI (OR 2.18; 95% CI, 1.32-3.60) and aCL (OR 1.98; 95% CI, 1.23-3.20). Among patients with established VTE, aPL positivity was associated with increased odds of recurrent events (pooled OR 1.65; 95% CI, 1.25-2.18). Findings were consistent across VTE subtypes and study designs. Using single aPL positivity as the reference group (6 studies, 1264 patients), the odds of recurrent thrombosis increased with greater aPL burden, being nearly twofold higher in patients with double positivity (OR 1.96; 95% CI, 0.85-4.55) and more than threefold higher in those with triple positivity (OR 3.13; 95% CI, 1.11-9.09). Higher aCL titers (>40 GPL/MPL units) were also associated with greater thrombotic risk compared with lower titers (OR 3.85; 95% CI, 1.75-8.33). Conclusions: In this meta-analysis with > 10,000 patients with VTE, aPL positivity was identified in approximately one in seven patients with VTE and was associated with increased odds of both first and recurrent events. A gradient of risk was observed, with double and triple aPL positivity and higher antibody titers conferring progressively greater thrombotic risk.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.